Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

44.32 -0.42 (-0.94%)
Streaming Delayed Price Updated: 12:32 PM EDT, Jul 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PTC Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Dell Technologies To Rally More Than 15%? Here Are 10 Other Analyst Forecasts For Tuesday
Raymond James increased the price target for Vital Energy, Inc. (NYSE: VTLE) from $54 to $67. Raymond James analyst John Freeman maintained an Outperform rating. Vital Energy shares rose 0.5% to $54.37... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 18, 2023
 
Via Benzinga
Where PTC Therapeutics Stands With Analysts
 
Via Benzinga
Raymond James Maintains Outperform Rating for PTC Therapeutics: Here's What You Need To Know
 
Via Benzinga
Earnings Scheduled For August 3, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. 
Via Benzinga
Where PTC Therapeutics Stands With Analysts
 
Via Benzinga
Micron Technology To Rally Around 22%? Here Are 10 Other Analyst Forecasts For Monday
Piper Sandler cut the price target for IBEX Limited (NASDAQ: IBEX) from $24 to $17. Piper Sandler analyst Arvind Ramnani maintained an Overweight rating. IBEX shares rose 0.3% to close at $13.59 on... 
Via Benzinga
US Stock Futures Edge Higher Amid Cautious Optimism; Analyst Says How Fed Packages Sept. Pause Key For Market Direction
US stock futures point to a higher opening on Monday after averages closed nearly flat in the week ended Sept. 15. 
Via Benzinga
Topics Economy
European Authority Gives Thumbs Down To PTC Therapeutics' Duchenne Therapy; Analyst Says It Can Overturn The Challenge
Friday morning, the Committee for Medicinal Products for Human Use of the European Medicines Agency gave a negative opinion on the conversion of the conditional marketing authorization to full... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Morgan Stanley Maintains Equal-Weight Rating for PTC Therapeutics: Here's What You Need To Know
 
Via Benzinga
What 15 Analyst Ratings Have To Say About PTC Therapeutics
 
Via Benzinga
14 Analysts Have This to Say About PTC Therapeutics
 
Via Benzinga
Why Novonix Shares Are Trading Higher By 27%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares jumped 127.8% to $0.1269. The company recently reported second-quarter results. 
Via Benzinga
Nasdaq Down Over 1%; US Industrial Output Rises In August
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% points on Friday. The Dow traded down 0.52% to 34,727.05 while the NASDAQ fell 1.31% to 13,743.78. The... 
Via Benzinga
Topics Stocks
PTC Therapeutics, Planet Fitness, Kemper And Other Big Stocks Moving Lower On Friday
U.S. stocks traded higher, with the Dow Jones falling around 180 points on Friday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Topics Stocks
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 169 companies set new 52-week lows. 
Via Benzinga
Dow Dips 100 Points; US Export Prices Rise 1.3% In August
U.S. stocks traded lower this morning, with the Dow Jones falling around 100 points on Friday. Following the market opening Friday, the Dow traded down 0.31% to 34,799.50 while the NASDAQ fell 1.09% to... 
Via Benzinga
Topics Stocks
PTC Therapeutics Crashes 29% After European Regulators Reject Its Muscular Dystrophy Drug
The company is working on a treatment for Duchenne muscular dystrophy. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2023
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases
Treating rare diseases is a tough but potentially lucrative business. With clinical trials coming due, here are three stocks to buy. 
Via InvestorPlace
PTC Therapeutics' Seizure Study Fails To Meet Primary Goal, Analyst Says Minimal Impact On Investment Thesis
PTC Therapeutics Inc (NASDAQ: PTCT) said its MIT-E trial of vatiquinone for mitochondrial disease-associated seizures (MDAS) failed to achieve its primary endpoint of  
Via Benzinga
PTC Therapeutics Says Interim Data For Huntington's Disease Candidate Shows Promise In Mid-Stage Study
PTC Therapeutics Inc (NASDAQ: PTCT) shared interim data from the 12-week portion of the PIVOT-HD Phase 2 study of PTC518 in  
Via Benzinga
3 High-Potential Small-Cap Stocks for Investors With Strong Stomachs
Small-cap stocks can be risky, and all three of these companies are facing adversity. But they could be home run investments. 
Via InvestorPlace
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against PTC Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Why America's Car-Mart Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares jumped 209.1% to $0.5622 after the United States Patent and Trademark Office granted the company a patent for certain medical systems and methods. 
Via Benzinga
PTC Therapeutics Stock Tumbles: Company Stops Preclinical Gene Therapy Programs After Failed Friedreich's Ataxia Study
 
Via Benzinga
Dow Falls Over 100 Points; Analog Devices Posts Upbeat Q2 Earnings
U.S. stocks traded lower this morning, with the Dow Jones dropping over 100 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.44% to 32,908.94 while the NASDAQ fell... 
Via Benzinga
Why Is Apexigen (APGN) Stock Up 31% Today?
Apexigen (APGN) stock is rising higher on Wednesday following news of a $16 million acquisition deal with Pyxis Oncology (PYXS). 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.